JP2020524179A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524179A5
JP2020524179A5 JP2020519007A JP2020519007A JP2020524179A5 JP 2020524179 A5 JP2020524179 A5 JP 2020524179A5 JP 2020519007 A JP2020519007 A JP 2020519007A JP 2020519007 A JP2020519007 A JP 2020519007A JP 2020524179 A5 JP2020524179 A5 JP 2020524179A5
Authority
JP
Japan
Prior art keywords
composition
composition according
mesenchymal stem
administered
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020519007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524179A (ja
JP7343123B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037725 external-priority patent/WO2018236680A1/en
Publication of JP2020524179A publication Critical patent/JP2020524179A/ja
Publication of JP2020524179A5 publication Critical patent/JP2020524179A5/ja
Application granted granted Critical
Publication of JP7343123B2 publication Critical patent/JP7343123B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020519007A 2017-06-19 2018-06-15 性機能低下の治療及び性的な生活の質の向上 Active JP7343123B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762521765P 2017-06-19 2017-06-19
US62/521,765 2017-06-19
PCT/US2018/037725 WO2018236680A1 (en) 2017-06-19 2018-06-15 TREATMENT OF SEXUAL DYSFUNCTION AND IMPROVEMENT OF THE QUALITY OF SEXUAL LIFE

Publications (3)

Publication Number Publication Date
JP2020524179A JP2020524179A (ja) 2020-08-13
JP2020524179A5 true JP2020524179A5 (enExample) 2021-07-29
JP7343123B2 JP7343123B2 (ja) 2023-09-12

Family

ID=62952383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519007A Active JP7343123B2 (ja) 2017-06-19 2018-06-15 性機能低下の治療及び性的な生活の質の向上

Country Status (12)

Country Link
US (1) US12496316B2 (enExample)
EP (1) EP3641793A1 (enExample)
JP (1) JP7343123B2 (enExample)
KR (1) KR20200017516A (enExample)
CN (1) CN111107858A (enExample)
AU (1) AU2018288653A1 (enExample)
CA (1) CA3067354A1 (enExample)
IL (1) IL271395A (enExample)
SG (1) SG11201912209UA (enExample)
TW (1) TW201919664A (enExample)
WO (1) WO2018236680A1 (enExample)
ZA (1) ZA201908451B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021340971A1 (en) 2020-09-08 2023-03-30 Longeveron, Inc. Treatment of Alzheimer's disease with allogeneic mesenchymal stem cells
EP4376950A1 (en) 2021-07-26 2024-06-05 Longeveron Inc. Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome
CA3226181A1 (en) 2021-09-10 2023-03-16 Longeveron Inc. Treatment of aging frailty comprising administering bone marriw derived mesenchymal stem cells
KR102762783B1 (ko) * 2022-01-21 2025-02-05 고현서 심리 프로파일에 따른 행동 습관 제공 방법, 서버, 저장 매체 및 디바이스
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
WO2007149548A2 (en) * 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
WO2010021996A1 (en) * 2008-08-18 2010-02-25 Junta De Beneficiencia De Guayaquil Treatment of injuries to the central nervous system
EP2486930B1 (en) 2009-10-06 2016-03-23 National University Corporation Nagoya University Cell preparation containing adipose tissue derived mesenchymal stem cells for use in the treatment of a condition of no urge to urinate
WO2013173694A2 (en) * 2012-05-18 2013-11-21 The Cooper Health System A method of restoring endothelial/smooth muscle architecture and cell signaling pathways to sexual organs
EA202190962A2 (ru) 2014-05-30 2022-02-28 Оникс Терапьютикс, Инк. Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом
CN105055450A (zh) 2015-02-13 2015-11-18 中国福利会国际和平妇幼保健院 人宫内膜干细胞在制备治疗卵巢早衰的药物中的应用

Similar Documents

Publication Publication Date Title
JP2020524179A5 (enExample)
Hickson et al. Challenges and opportunities for stem cell therapy in patients with chronic kidney disease
Kebriaei et al. Treatment of graft-versus-host-disease with mesenchymal stromal cells
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
JP2015524849A5 (enExample)
RU2013108248A (ru) Иммуногенные противовоспалительные композиции
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
Colpo et al. Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders
CO6630139A2 (es) Aptámeros par b-bgf y su uso en el tratamiento de enfermedades y transtornos mediados por b-ngf
MX375745B (es) Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada.
CA2747794A1 (en) Treatment of lung and pulmonary diseases and disorders
MX2015005148A (es) Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.
MX2022013590A (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
SG10201903210WA (en) Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders
JP2009545620A5 (enExample)
NZ578928A (en) Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases
CO2020016052A2 (es) Receptores del factor de crecimiento quimérico
JP2016530284A5 (enExample)
CO6771406A2 (es) Una composición combinada
MX376783B (es) Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes.
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
NZ597680A (en) Pharmaceutical composition for relieving pain in a joint disease
AR082501A1 (es) Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same